Stelios Pharmaceuticals LLP
About Stelios Pharmaceuticals LLP
Data last updated:
Stelios Pharmaceuticals LLP is a limited liability partnership (LLP) based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 May 2012 and has been in existence for over 14 years.
The LLP is registered with the Registrar of Companies (ROC), Mumbai, under LLPIN AAA-9161. Its GSTIN is 27ACDFS1025N1Z1 (Maharashtra).
The LLP has a total obligation of contribution of ₹30 Lakh. It is led by designated partners Venkateswaran Kailasam Kalpathy and Vasanthi Venkateswaran.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at 2106 B – Wing Sahyadri Appartments Upper Govind Nagar Malad East Near Upvan Towers, Mumbai, Maharashtra, India – 400064.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address2106 B – Wing Sahyadri Appartments Upper Govind Nagar Malad East Near Upvan Towers, Mumbai, Maharashtra, India – 400064
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Stelios Pharmaceuticals LLP FY 2025 filings available
Financial Statement Summary of Stelios Pharmaceuticals LLP
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Income | •••• | •••• | •••• | •••• | •••• |
| Purchases and Direct Costs | •••• | •••• | •••• | •••• | •••• |
| Personnel Expenses | •••• | •••• | •••• | •••• | •••• |
| Administrative Expenses | •••• | •••• | •••• | •••• | •••• |
| Interest | •••• | •••• | •••• | •••• | •••• |
| Depreciation | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax | •••• | •••• | •••• | •••• | •••• |
| Profit After Tax | •••• | •••• | •••• | •••• | •••• |
| Profit Transferred to Partners | •••• | •••• | •••• | •••• | •••• |
| Assets and Liabilities | |||||
| Partners' Contribution | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Secured Loans | •••• | •••• | •••• | •••• | •••• |
| Unsecured Loans | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Other Liabilities and Provisions | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Loans and Advances | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Stelios Pharmaceuticals LLP
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | •••• | •••• | •••• | •••• | •••• |
| Return on Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Return on Assets | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt to Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Turnover Growth | •••• | •••• | •••• | •••• | •••• |
| Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form 8. The full year-wise statements and ratios of Stelios Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Designated Partners of Stelios Pharmaceuticals LLP
Stelios Pharmaceuticals has 2 designated partners on record. No former designated partners are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Venkateswaran Kailasam Kalpathy | Designated Partner | 10 May 2012 | 14 Years 5 Months | Current |
| Vasanthi Venkateswaran | Designated Partner | 10 May 2012 | 14 Years 5 Months | Current |
Charges & Borrowings of Stelios Pharmaceuticals LLP
Stelios Pharmaceuticals LLP does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Stelios Pharmaceuticals LLP
Employment history and EPFO contributions of people linked to Stelios Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Stelios Pharmaceuticals LLP
Stelios Pharmaceuticals LLP has 2 designated partner changes on record since 2012: 2 appointments. The latest: Vasanthi Venkateswaran was appointed as Designated Partner on 10 May 2012.
Credit Ratings, Litigation & Regulatory Alerts for Stelios Pharmaceuticals LLP
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Stelios Pharmaceuticals LLP
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Stelios Pharmaceuticals LLP
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Stelios Pharmaceuticals LLP
Stelios Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27ACDFS1025N1Z1 | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Stelios Pharmaceuticals LLP
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stelios Pharmaceuticals LLP
Stelios Pharmaceuticals is an active limited liability partnership based in Mumbai, Maharashtra, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 10 May 2012 (14+ years old) and is registered under LLPIN AAA-9161.
Stelios Pharmaceuticals has 2 current designated partners:
- Venkateswaran Kailasam Kalpathy - Designated Partner
- Vasanthi Venkateswaran - Designated Partner
The GSTIN of Stelios Pharmaceuticals is 27ACDFS1025N1Z1, registered in Maharashtra.
The LLPIN (Limited Liability Partnership Identification Number) of Stelios Pharmaceuticals is AAA-9161. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Stelios Pharmaceuticals was incorporated on 10 May 2012, making it 14+ years old. It is registered with the Registrar of Companies, Mumbai.
Vasanthi Venkateswaran was appointed as Designated Partner on 10 May 2012. Venkateswaran Kailasam Kalpathy was appointed as Designated Partner on 10 May 2012.
The registered office of Stelios Pharmaceuticals is at 2106 B – Wing Sahyadri Appartments Upper Govind Nagar Malad East Near Upvan Towers, Mumbai, Maharashtra, India – 400064.
The total obligation of contribution is ₹30 Lakh.
Stelios Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Stelios Pharmaceuticals can be reached at its registered office: 2106 B – Wing Sahyadri Appartments Upper Govind Nagar Malad East Near Upvan Towers, Mumbai, Maharashtra, India – 400064.